M.B.A., finance and business policy, Graduate School of Business, The University of Chicago; M.A., University of California, Irvine; B.A., Sarah Lawrence College
Summary of Experience
Mr. Tuttle specializes in helping both new and established companies grow. He is expert in evaluating market and customer needs, developing new products and services, adapting business structures to meet changing competitive requirements, and employing acquisition and divestiture to improve performance. In the area of new product and service development, he has worked with clients to identify the portfolio of innovations that will create the most value and to enhance the effectiveness with which those innovations are developed and brought to market. Mr. Tuttle has assisted clients in expanding their presence in both new and existing markets, evaluating potential investments, and supporting the acquisition and integration of target companies and product lines. For Fortune 100 clients in health care, transportation, and technology, as well as many smaller clients, his projects have often included development of sophisticated models for evaluating market demand, product success, and business options. He writes and speaks frequently on growth and innovation.
Delays in pulmonary decline in eteplirsen-treated patients with Duchenne muscular dystrophy
Muscle & Nerve, 2022
Iff J, Gerrits C, Zhong Y, Tuttle E, Birk E, Zheng Y, Paul X, Henricson EK, McDonald CM, CINRG-DNHS Investigators
Disease Progression Stages and Burden in Patients with Duchenne Muscular Dystrophy Using Administrative Claims Supplemented by Electronic Medical Records
Advances in Therapy, 2022
Iff J, Zhong Y, Gupta D, Paul X, Tuttle E, Henricson E, Schrader R, CINRG DNHS Investigators
Development of a classifier to identify patients with probable Lennox-Gastaut syndrome in health insurance claims databases via random forest methodology
Current Medical Research and Opinion, 2019
Vekeman F, Piña-Garza JE, Cheng WY, Tuttle E, Giguère-Duval P, Oganisian A, Damron J, Duh MS, Shen V, Saurer TB, Montouris GD, Isojarvi J
Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014
Diabetes Therapy. Jun 23 2017
Carls G, Huynh J, Tuttle E, Yee J, Edelman SV
Assessment of treatment patterns and healthcare costs associated with probable Lennox-Gastaut syndrome
Epilepsy & Behavior. Aug 2017;73:46-50
Piña-Garza JE, Montouris GD, Vekeman F, Cheng WY, Tuttle E, Giguere-Duval P, Duh MS, Shen V, Saurer TB, Isojarvi J
Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes
Diabetes Care. 2017;40(11):1469-1478
Carls GS, Tuttle E, Tan RD, Huynh J, Yee J, Edelman SV, Polonsky WH
Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication ad
Obesity Science and Practice. September 2017;3(3):342-351
Carls GS, Tan R, Zhu JY, Tuttle E, Yee J, Edelman SV, Polonsky WH
Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study
Hospital Practice. Feb 2017;45(1):1-8
Advanced Diagnostics: Innovation, Reimbursement, and Coverage Challenges
IN VIVO, October 2014
Do Electric Cars Make Economic Sense for the Mass Market?
The U.S. Electric Car Race: What Do Consumers Really Want?
Authorized Generic Drugs, Price Competition, And Consumers’ Welfare
Health Affairs - 26, no. 3 (2007): 790-799
Berndt E, Parece A, Tuttle E, Mortimer R, Bhattacharjya A
Prevalence, referral patterns, testing, and surgery in aortic valve disease: leaving women and elderly patients behind?
J Heart Valve Dis 2007 Jul;16(4):362-9
Bach D, Ivanova J, Birnbaum H, Fournier A, Tuttle E
Economic burden and co-morbidities of atrial fibrillation in a privately insured population
Curr Med Res Opin. 2005 Oct;21(10):1693-9.
Wu EQ, Birnbaum HG, Mareva M, Tuttle E, Castor AR, Jackman W, Ruskin J.
Your Patent Is About to Expire: What Now?
Pharmaceutical Executive 2004 Nov.
Tuttle E, Parece A, Hector A
Beyond Lifecycle Management - Optimizing Performance Following Patent Expiry
Tuttle E, Parece A, Hector A
A Comprehensive Approach to Corporate Venturing
2001 Handbook of Business Strategy
Tuttle E, Getz G
Free Radicals: Why Industry Leaders Fail to Harness Disruptive Technologies
Tuttle E, Christensen C